Investor Presentaiton slide image

Investor Presentaiton

Investor presentation ADA 2019 Slide 13 An overview of the PIONEER programme Diet and exercise k OAD PIONEER 1 Insulin users PIONEER 2 vs SGLT-2 (Met) PIONEER 8 vs placebo (Diet and exercise) PIONEER 3 vs DPP-4 (1-2 OADs: Met + SU) PIONEER 4 vs GLP-1/placebo (1-2 OADs: Met ± SGLT-2) PIONEER 7 Flexible dose adjustment vs DPP-4 with extension (1-2 OADs: Met, SU, TZD, SGLT-2) Add-on to insulin (Insulin + Met) Special populations PIONEER 5 Renal impairment (± Met, ± SU, or ± insulin) PIONEER 6 CVOT (Standard of care) PIONEER 9 vs GLP-1/placebo, Japan (Monotherapy) PIONEER 10 vs GLP-1/placebo, Japan (1 OAD: SU, TZD, a-GI, glinide or SGLT-2) Note: Text in parentheses represents allowed background medications. CVOT: cardiovascular outcomes trial; DPP-4: dipeptidyl peptidase-4 inhibitor; GLP-1: glucagon-like peptide-1 receptor agonist; Met: metformin; OAD: oral anti-diabetes drug; PIONEER: peptide innovation for early diabetes treatment; SGLT-2: sodium glucose co-transporter-2 inhibitor; SU: sulphonylurea; TZD: thiazolidinedione; a-GI: alpha-glucosidase inhibitors; glinide: prandial glucose regulators. novo nordisk
View entire presentation